Cell Pouch System developer Sernova announces CEO transition - Mass Device

[Image from Sernova]

Sernova announced contiguous that, arsenic portion of a planned enactment succession process, Dr. Philip Toleikis volition modulation retired of the CEO role.

Toleikis spent 13 years starring the Cell Pouch System developer arsenic president and CEO. He remains an enforcement astatine the institution arsenic the planned modulation moves him to main exertion serviceman (CTO). Additionally, Toleikis volition stay CEO during the company’s hunt period.

Get the afloat communicative astatine our sister site, Drug Delivery Business News.